Laisalmi 2001a.

Methods	Study design: parallel RCT Study duration: not reported Study follow‐up: 2 POD
Participants	Country: Finland Setting: single centre Inclusion criteria: ASA physical status I‐II women scheduled to undergo elective breast surgery Number: treatment group (15); control group (15) Mean age ± SD (years): treatment group (49 ± 7); control group (45 ± 9) Sex (M/F): all female Exclusion criteria: patients with abnormal kidney or hepatic function
Interventions	Treatment group 30 mg ketorolac: 30 mg IM with the premedication, "at the end of," and 6 h after anaesthesia Control group Saline: 3 IM injections
Outcomes	Kidney function was assessed using sensitive markers that monitor the function of different entities of the kidney at after 2h of anaesthesia, 2 and 12h after the end of anaesthesia, as well as on the first and on the second POD: U‐NAG/creat for proximal tubular function, PuO2 is a marker of medullary homeostasis, and EPO that of the tubulointerstitium The traditional function markers such as SCr and urea were also measured at 12 h after the end of anaesthesia, and on the first and second POD Urine output
Notes	Funding Source: Helsinki University Central Hospital EVO Grant
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study was described as randomised, method of randomisation was not reported
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data
Selective reporting (reporting bias)	Low risk	Study protocol matches outcomes presented
Other bias	Low risk	Non‐profit organisation funding received